Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of KW-0761 in HTLV-1 Associated Myelopathy (HAM)
jRCT1091220324Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in HTLV-1-associated myelopathy (HAM) comparing KW-0761 with Placebo (2 arms). Primary endpoint: Improvement in Osame's motor disability score. Started Jan 2018; status: completed.
02
Drugs
mogamulizumab
03
Conditions
HTLV-1-associated myelopathy (HAM)
Beyond the preview
Go deeper on jRCT1091220324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1091220324.